The 340B drug pricing program is not going away. No federal legislation has been enacted to eliminate it, and no executive order has been issued to shut it down. But the program is under more pressure than at any point in its history, facing challenges from drug manufacturers, congressional reform efforts, and ongoing court battles that are reshaping how it works in practice.
In 2024, covered entities purchased $81.4 billion in discounted drugs through 340B, representing roughly 16% of the $494.9 billion in total U.S. prescription drug spending that year. A program that large doesn’t disappear quietly, but it is changing fast.
What the 340B Program Actually Does
The 340B program requires drug manufacturers to sell outpatient medications at steep discounts to hospitals and clinics that serve low-income and uninsured patients. These organizations, called “covered entities,” include federally qualified health centers, rural hospitals, children’s hospitals, and certain cancer centers. The gap between what they pay for a drug and what insurers reimburse generates revenue that covered entities can use to fund services for vulnerable populations.
The program has no direct cost to taxpayers. Instead, manufacturers absorb the discount as a condition of having their drugs covered by Medicaid. That structure is part of why the program has survived for more than 30 years, but it’s also why manufacturers have grown increasingly aggressive in trying to limit its reach.
Why Manufacturers Are Pushing Back
The biggest practical threat to 340B isn’t a bill in Congress. It’s drug companies restricting discounts on their own. Over a dozen major manufacturers, including Eli Lilly, Johnson & Johnson, Amgen, and GSK, have posted notices to covered entities through HRSA imposing new conditions on 340B pricing, particularly when drugs are dispensed through contract pharmacies rather than an entity’s own in-house pharmacy.
Contract pharmacies are a central flashpoint. Many covered entities, especially small community health centers, don’t operate their own pharmacies. They partner with retail pharmacies to dispense 340B drugs to their patients. Manufacturers argue this system has expanded far beyond its original intent and creates opportunities for abuse. Covered entities counter that without contract pharmacies, patients in rural and underserved areas simply can’t access their medications at 340B prices.
Starting around 2020, several large manufacturers began refusing to ship 340B-priced drugs to contract pharmacies unless covered entities submitted detailed claims data. Some restricted discounts to a single contract pharmacy per entity. These moves effectively cut off 340B savings for thousands of organizations overnight.
Where the Courts Stand
The legal battles over contract pharmacy restrictions have produced a string of results that favor covered entities, at least at the state level. Multiple states have passed laws prohibiting manufacturers from restricting 340B pricing to contract pharmacies. Arkansas was among the first, enacting a law in 2021 that prevents manufacturers from blocking pharmacies from contracting with covered entities.
The pharmaceutical industry’s trade group, PhRMA, challenged the Arkansas law, arguing it conflicted with the federal 340B statute and violated the Commerce Clause. A federal district court disagreed, and the Eighth Circuit Court of Appeals affirmed that ruling. The core question on appeal was whether the federal 340B statute preempts state laws designed to protect contract pharmacy arrangements.
Mississippi passed a similar law, and in April 2026 the Fifth Circuit upheld it against challenges from both Novartis and PhRMA. The same court had already rejected a similar challenge by AbbVie in September 2025. These rulings are building a pattern of federal courts siding with states that protect 340B contract pharmacy access, though the issue could eventually reach the Supreme Court.
Federal Oversight Is Tightening
HRSA, the federal agency that administers 340B, finalized a major rule in April 2024 overhauling how disputes between manufacturers and covered entities get resolved. The previous system, established in 2020, was modeled on formal courtroom litigation, with federal rules of evidence and civil procedure. In practice, it was so cumbersome that almost no disputes were actually resolved.
The new process is designed to be faster and more accessible. Panels of subject matter experts from HRSA’s Office of Pharmacy Affairs now handle claims, with an expectation that decisions come within one year. There’s no minimum dollar threshold to file a claim, which matters for smaller community health centers that couldn’t justify the cost of a complex legal proceeding over a relatively modest dispute. Both parties must attempt good-faith resolution before filing, and either side can request reconsideration of a panel’s decision. The Secretary of Health and Human Services retains authority to review, alter, or reverse any outcome.
This matters because it gives covered entities a realistic path to challenge manufacturers who restrict 340B pricing. Before this rule, manufacturers could impose restrictions knowing that the federal dispute process was essentially non-functional.
The Rebate Model Pilot That Was Scrapped
One proposal that generated significant concern was a 340B Rebate Model Pilot Program, which would have restructured how discounts flow in the program. In February 2026, a federal district court in Maine vacated the pilot program’s application notice and sent it back to HHS for reconsideration. As of now, HHS is reconsidering whether to implement the pilot at all. This was not an attempt to end 340B, but it represented a significant structural shift that many covered entities opposed.
Congressional Reform, Not Elimination
Bills related to 340B are introduced in nearly every session of Congress, but they focus on reforming the program rather than eliminating it. The Rural 340B Access Act of 2025, introduced on the first day of the 119th Congress, was referred to the House Energy and Commerce Committee. The political dynamics around 340B make outright elimination unlikely: the program serves rural hospitals, cancer centers, and community health clinics that have strong bipartisan constituencies.
That said, reform proposals vary widely. Some would impose new transparency requirements on how covered entities use 340B savings. Others would tighten eligibility or limit the use of contract pharmacies. The pharmaceutical industry has pushed for requirements that 340B savings flow directly to patients at the pharmacy counter, rather than being used by hospitals for general operations.
Does 340B Actually Help Patients?
This is where the debate gets uncomfortable for the program’s defenders. Research published in Health Affairs found little relationship between hospitals’ 340B participation and increased access to care for uninsured or low-income patients. The program generates substantial revenue for covered entities, but how that money gets used varies enormously. Some organizations fund free clinics, sliding-scale pharmacies, and outreach programs. Others absorb the revenue into general operating budgets.
This lack of accountability is the strongest argument reformers have. The program was designed to help safety-net providers stretch scarce resources, but there’s no federal requirement that 340B savings be spent on any specific patient-facing service. That gap fuels both legitimate reform efforts and manufacturer arguments for restricting discounts.
At the same time, many covered entities argue that 340B revenue is woven into their financial survival. When states have attempted to change how 340B interacts with Medicaid, covered entities have pushed back hard, warning of service cuts. New York, for example, was required to make additional payments to covered entities over a transition period after changing its approach.
What This Means Going Forward
The 340B program has strong legal footing, bipartisan support in its basic mission, and a $81 billion footprint that makes it deeply embedded in the healthcare system. It is not being eliminated. But the version of 340B that exists five years from now will likely look different from today’s program. Manufacturer restrictions, state protection laws, federal court rulings, and potential congressional action are all reshaping the boundaries of who gets discounts, through which pharmacies, and under what conditions. If you’re a patient, provider, or pharmacy that relies on 340B, the program isn’t disappearing, but the rules of engagement are actively being rewritten.